2.

拓扑替康治疗复发SCLC的随机临床试验

Randomized studies of single-agent topotecan for relapsed SCLC

Study	Phase	Regimen	n	RR (%)	MST (week)
iv: intravenous injection; BSC: best support care; CAV: CTX/ADM/VCR.
Von Pawel[7]	Ⅱ	Oral topotecan	52	23.0	32.0
		iv topotecan	54	15.0	25.0
Eckardt[8]	Ⅲ	Oral topotecan	153	18.3	33.0
		iv topotecan	151	21.9	35.0
O’Brien[9]	Ⅲ	BSC	67	–	13.9
		Topotecan	70	7.0	25.9
Von Pawel[10]	Ⅲ	CAV	104	18.3	24.7
		Topotecan	107	24.3	25.0